ABL1 and acute myeloid leukemia: AXL-selective TKIs have shown promise in preclinical models, particularly in combination with targeted BCR-ABL and FLT3 inhibition in CML and AML, respectively, and clinical trials are currently underway combining AXL inhibition with standard chemotherapy in AML.